Dec 11, 2025 • 7:00 am EST Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss
Dec 10, 2025 • 4:01 pm EST Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025
Nov 12, 2025 • 8:00 am EST Corbus Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
Oct 18, 2025 • 3:00 am EDT Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25
Oct 7, 2025 • 8:00 am EDT Corbus Pharmaceuticals to Participate in the Upcoming Piper Sandler Virtual Oncology Symposium
Sep 22, 2025 • 8:00 am EDT Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ESMO 2025